Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Angiogenesis Inhibitors
Antibiotics, Antineoplastic
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Breast Neoplasms
Colorectal Neoplasms
Disease-Free Survival
Doxorubicin
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Maximum Tolerated Dose
Middle Aged
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Protein Kinase Inhibitors
Sirolimus

authors with profiles

John Moroney